ZFIN ID: ZDB-FISH-200521-6
Fish name: WT + CRISPR1-myo9aa + CRISPR1-myo9ab + CRISPR2-myo9aa + CRISPR2-myo9ab
Genotype: WT
Targeting Reagent: CRISPR1-myo9aa, CRISPR2-myo9aa, CRISPR1-myo9ab, CRISPR2-myo9ab
HUMAN DISEASE MODELED by WT + CRISPR1-myo9aa + CRISPR1-myo9ab + CRISPR2-myo9aa + CRISPR2-myo9ab
Human Disease Conditions Citations
congenital myasthenic syndrome standard conditions O'Connor et al., 2019
GENE EXPRESSION
Gene expression in WT + CRISPR1-myo9aa + CRISPR1-myo9ab + CRISPR2-myo9aa + CRISPR2-myo9ab
RNA expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in WT + CRISPR1-myo9aa + CRISPR1-myo9ab + CRISPR2-myo9aa + CRISPR2-myo9ab
Phenotype Conditions Figures
heart edematous, abnormal standard conditions Fig. 1 with image from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber amount, ameliorated chemical treatment by injection: peptide Fig. 5 with imageFig. T2 from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber decreased amount, abnormal standard conditions Fig. 4 with imageFig. 5 with imageFig. T2 from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber decreased amount, abnormal chemical treatment by environment: fasudil hydrochloride Fig. 5 with image from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber decreased amount, exacerbated chemical treatment by environment: fasudil hydrochloride Fig. T2 from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber decreased size, abnormal standard conditions Fig. T1 from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber size, ameliorated chemical treatment by environment: fasudil hydrochloride Fig. T1 from O'Connor et al., 2019
horizontal myoseptum neuromuscular junction of skeletal muscle fiber size, ameliorated chemical treatment by injection: peptide Fig. T1 from O'Connor et al., 2019
horizontal myoseptum synaptic vesicle ab-sv2 labeling absent, abnormal standard conditions Fig. 3 with image from O'Connor et al., 2019
horizontal myoseptum synaptic vesicle ab-sv2 labeling amount, ameliorated chemical treatment by environment: fasudil hydrochloride Fig. 3 with image from O'Connor et al., 2019
horizontal myoseptum synaptic vesicle ab-sv2 labeling amount, ameliorated chemical treatment by injection: peptide Fig. 3 with image from O'Connor et al., 2019
motor neuron axon branchiness, ameliorated chemical treatment by injection: peptide Fig. 5 with image from O'Connor et al., 2019
motor neuron axon decreased branchiness, abnormal standard conditions Fig. 5 with image from O'Connor et al., 2019
motor neuron axon decreased branchiness, abnormal chemical treatment by environment: fasudil hydrochloride Fig. 5 with image from O'Connor et al., 2019
motor neuron axon decreased length, abnormal chemical treatment by environment: fasudil hydrochloride Fig. T1 from O'Connor et al., 2019
motor neuron axon decreased length, abnormal standard conditions Fig. 3 with imageFig. T1 from O'Connor et al., 2019
motor neuron axon length, ameliorated chemical treatment by injection: peptide Fig. T1 from O'Connor et al., 2019
myotome decreased size, abnormal chemical treatment by environment: fasudil hydrochloride Fig. T3 from O'Connor et al., 2019
myotome decreased size, abnormal standard conditions Fig. T1Fig. T3 from O'Connor et al., 2019
myotome decreased size, exacerbated chemical treatment by injection: peptide Fig. T1 from O'Connor et al., 2019
myotome size, ameliorated chemical treatment by environment: fasudil hydrochloride Fig. T1 from O'Connor et al., 2019
myotome size, ameliorated chemical treatment by injection: peptide Fig. T3 from O'Connor et al., 2019
myotome synapse ab-sv2 labeling decreased amount, abnormal standard conditions Fig. T2 from O'Connor et al., 2019
thigmotaxis decreased linear velocity, abnormal standard conditions Fig. 2 from O'Connor et al., 2019
thigmotaxis process quality, ameliorated chemical treatment by environment: fasudil hydrochloride Fig. 2 from O'Connor et al., 2019
thigmotaxis process quality, ameliorated chemical treatment by injection: peptide Fig. 2 from O'Connor et al., 2019
whole organism behavioural activity, ameliorated chemical treatment by injection: peptide Fig. 2 from O'Connor et al., 2019
whole organism curved, abnormal standard conditions Fig. 1 with image from O'Connor et al., 2019
whole organism decreased behavioural activity, abnormal standard conditions Fig. 2 from O'Connor et al., 2019
whole organism movement behavioral quality, abnormal standard conditions Fig. 2 from O'Connor et al., 2019
whole organism movement behavioral quality, ameliorated chemical treatment by injection: peptide Fig. 2 from O'Connor et al., 2019
whole organism viability, ameliorated chemical treatment by environment: fasudil hydrochloride Fig. 2 from O'Connor et al., 2019
whole organism viable, normal standard conditions Fig. 2 from O'Connor et al., 2019

CITATIONS  (1)